06
News BRIEFS MS Trial Alert: Investigators Recruiting 250 People with Primaryor SecondaryProgressive MS for Study of Oral Ibudilast Investigators are recruiting for a phase II clinical trial of ibudilast (MN-166, MediciNova, Inc.), an oral agent, in 250 people with progressive forms of MS. The study, called the SPRINT-MS trial, is principally funded by the National Institutes of Neurological Diseases and Stroke (NINDS), with additional support by MediciNova, the company that will supply ibudilast, and the National MS Society. The study will be conducted through the NeuroNEXT Network, a clinical trials initiative
MS connection: SUMMER 2014
of the National Institutes of Health. Robert Fox, MD (Cleveland Clinic Foundation) is the principal investigator. For the full article, visit www.nationalmssociety. org/About-the-Society/ News/MS-Trial-AlertInvestigators-Recruiting250-People
International Committee ReExamines Definitions of the Courses of MS Multiple sclerosis manifests itself in many different ways and different courses, and the path of an individual’s MS is usually defined by patterns of symptoms, such as whether they come and go or remain or get worse. Having more refined definitions of different types of MS would greatly facilitate research studies, communications between people with MS and their healthcare providers, and treatment decisions. For these reasons, a recent effort to fine-tune descriptions of MS was undertaken
by the International Advisory Committee on Clinical Trials in MS. This committee is comprised of international leaders in MS research and clinical care and is jointly supported by the National MS Society and the European Committee for Treatment and Research in MS (ECTRIMS). For the full article, visit www.nationalmssociety. org/About-the-Society/ News/InternationalCommittee-Re-ExaminesDefinitions-of
Genzyme Announces: FDA Accepts Its Resubmitted Application for Lemtrada Genzyme, a Sanofi company, announced that the U.S. Food and Drug Administration had accepted for review the company’s resubmission of an application seeking approval of Lemtrada™ (alemtuzumab) as a treatment for relapsing MS in the United States.